Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy

Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of <10% due in part to a lack of effective therapies. Pan-histone deacetylase (HDAC) inhibitors have shown preclinical efficacy against PDAC but have failed in the clinic due to toxicity. Selective HDAC inhibitors may reduce to...

Descripción completa

Detalles Bibliográficos
Autores principales: Laschanzky, Richard S., Humphrey, Lisa E., Ma, Jihyun, Smith, Lynette M., Enke, Thomas J., Shukla, Surendra K., Dasgupta, Aneesha, Singh, Pankaj K., Howell, Gillian M., Brattain, Michael G., Ly, Quan P., Black, Adrian R., Black, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770665/
https://www.ncbi.nlm.nih.gov/pubmed/31500290
http://dx.doi.org/10.3390/cancers11091327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770665/
https://www.ncbi.nlm.nih.gov/pubmed/31500290
http://dx.doi.org/10.3390/cancers11091327

Ejemplares similares